References
Esworthy RS, Doroshow JH, Chu FF. The beginning of GPX2 and 30 years later. Free Radic Biol Med. 2022;188:419–33.
Hashinokuchi A, Matsubara T, Ono Y, et al. Clinical and prognostic significance of glutathione peroxidase 2 in lung adenocarcinoma. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15116-z.
Peng F, Xu Q, Jing X, et al. GPX2 promotes EMT and metastasis in non-small cell lung cancer by activating PI3K/AKT/mTOR/Snail signaling axis. FASEB Bioadv. 2023;5:233–50.
Wang M, Chen X, Fu G, et al. Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS-mutated lung cancer cells. Oncol Rep. 2022;48:207.
Ahmed KM, Veeramachaneni R, Deng D, et al. Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer. 2022;10:e004752.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article refers to: Hashinokuchi, A, Matsubara, T, Ono Y, et al. Clinical and prognostic significance of glutathione peroxidase 2 in lung adenocarcinoma. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15116-z.
Rights and permissions
About this article
Cite this article
Hashinokuchi, A., Matsubara, T., Takenaka, T. et al. ASO Author Reflections: Impact of Glutathione Peroxidase 2 (GPX2) in Lung Adenocarcinoma. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15177-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1245/s10434-024-15177-0